Physician profile
Charles E Huggins
NPI 1578518882
$2,644.62
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $168 · 2021: $163 · 2022: $626 · 2023: $513 · 2024: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $374.15 | 2022-2024 | |
| Abbvie INC. | $335.13 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.41 | 2019-2024 | |
| Astellas Pharma US INC | $186.69 | 2022-2024 | Veozah, Myrbetriq |
| Organon LLC | $151.35 | 2021-2024 | Nexplanon |
| Sage Therapeutics, LLC | $139.54 | 2024 | |
| Channel Medsystems, INC. | $130.53 | 2022-2023 | |
| Pfizer INC. | $114.76 | 2019-2023 | |
| Myovant Sciences INC. | $111.99 | 2022 | |
| Therapeuticsmd, INC. | $106.85 | 2019-2022 | |
| Shield Therapeutics INC | $86.47 | 2023-2024 | Accrufer |
| Duchesnay USA Incorporated | $54.33 | 2019 | |
| Lupin INC. | $50.05 | 2019-2020 | |
| Exeltis, USA INC. | $48.19 | 2023-2024 | Slynd |
| Merck Sharp & Dohme LLC | $46.71 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $45.26 | 2022 | |
| Avion Pharmaceuticals | $44.58 | 2019-2021 | |
| Novo Nordisk INC | $41.37 | 2019-2020 | |
| Daiichi Sankyo INC. | $40.65 | 2019 | |
| Amag Pharmaceuticals, INC. | $39.19 | 2019 | |
| Hologic Sales and Service, LLC | $34.78 | 2019-2020 | |
| Evofem Biosciences, INC. | $31.45 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $28.67 | 2024 | Myfembree |
| Abbott Laboratories | $24.75 | 2019 | |
| Allergan, INC. | $24.47 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $24.13 | 2022 | |
| Aspira Women'S Health INC | $23.04 | 2022 | |
| Amgen INC. | $22.32 | 2019 | |
| Exact Sciences Corporation | $18.53 | 2023 | Cologuard Collection Kit |
| Roche Diagnostics Corporation | $17.91 | 2019 | |
| Medtronic, INC. | $16.11 | 2022 | |
| Millicent US INC | $15.67 | 2019 | |
| Agile Therapeutics, INC. | $14.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Huggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.